Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 | P05230 | 3/20 | 0.45 |
| ▸ | SERPINC1 | P01008 | 3/20 | 0.39 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 4/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | GJB2 | P29033 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15281442 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL15281431 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL10943934 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7147865 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7146052 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL12082938 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7636758 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL7151360 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL17664724 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 | |
| SCHEMBL6078563 | 1.00 | FGF1 (0.45) | FGF1SERPINC1HPSEF10SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8180444-B2 | Enhanced PhotoDynamic Therapy with immune system assist | BIOLITEC PHARMA MARKETING LTD (MY) | 2012-05-15 | — | — | US | disclosed |
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
| US-7521551-B2 | Chlorins possessing fused ring systems useful as photoselective compounds for photodynamic therapy | MIRAVANT PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090062719-A1 | Enhanced PhotoDynamic Therapy with Immune System Assist | BIOLITEC UNTERNEHMENSBETEILIGUNGS II AG (AT) | 2009-03-05 | — | — | US | disclosed |
| US-20080275232-A1 | CHLORINS POSSESSING FUSED RING SYSTEMS USEFUL AS PHOTOSELECTIVE COMPOUNDS FOR PHOTODYNAMIC THERAPY | MIRAVANT PHARMACEUTICALS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-7022843-B1 | β,β′-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2006-04-04 | — | — | US | disclosed |
| EP-1251828-A4 | LOCAL DRUG DELIVERY USING PHOTOSENSITIZER-MEDIATED AND ELECTROMAGNETIC RADIATION-ENHANCED VASCULAR PERMEABILITY | MIRAVANT MEDICAL TECHNOLOGIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050226810-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | MIRAVANT PHARMACEUTICALS, INC. | 2005-10-13 | — | — | US | disclosed |
| US-20050137180-A1 | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy | MIRAVANT PHARMACEUTICALS, INC. | 2005-06-23 | — | — | US | disclosed |
| US-6906050-B2 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | MIRAVANT PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-0804439-A1 | BETA, BETA '-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, BACTERIOCHLORINS, AND METHODS FOR MAKING THE SAME FROM BETA ,BETA '-UNSUBSTITUTED TETRAPYRROLIC MACROCYCLES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1997-11-05 | — | — | EP | disclosed |
| US-5656756-A | PHOTOSENSITIZERS IN PHOTODYNAMIC THERAPY, ANTITUMOR AGENTS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1997-08-12 | — | — | US | disclosed |
| US-5648485-A | PORPHYRIN COMPOUNDS | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1997-07-15 | — | — | US | disclosed |
| WO-1996016966-A1 | MESO-MONOIODO-SUBSTITUTED TETRAMACROCYCLIC COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | QUADRA LOGIC TECHNOLOGIES, INC. (CA) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996013504-A1 | β,β'-DIHYDROXY MESO-SUBSTITUTED CHLORINS, ISOBACTERIOCHLORINS, BACTERIOCHLORINS, AND METHODS FOR MAKING THE SAME FROM β,β'-UNSUBSTITUTED TETRAPYRROLIC MACROCYCLES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1996-05-09 | — | — | WO | disclosed |
| WO-1995029914-A1 | A METHOD OF SYNTHESIZING 5,15-DIARYLBENZOCHLORIN-7-ONE COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-11-09 | — | — | WO | disclosed |
| EP-0263027-B1 | GLYCOSIDATION CATALYST AND PROCESS FOR PREPARING GLYCOSIDE DERIVATIVES | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1990-11-14 | — | — | EP | disclosed |
| US-4874852-A | Glycosidation catalust and process for preparing glycoside derivatives | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| EP-0263027-A1 | Glycosidation catalyst and process for preparing glycoside derivatives | NIPPON FINE CHEMICAL CO., LTD. (JP) | 1988-04-06 | — | — | EP | disclosed |
| US-4524067-A | OXIDATION RESISTANCE FOR FOODS AND COSMETICS; PROMOTES METABOLISM AND SUPPRESSES PEROXIDATION OF LIPIDS | OSAKA CHEMICAL LABORATORY CO., LTD. (JP) | 1985-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201793-A1 | PROCESS FOR PRODUCTION OF GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVE | GCGR, UGGT1, GCKR | FGF1 533/4885SERPINC1 489/4885HPSE 1746/4885 |
| US-20080275232-A1 | CHLORINS POSSESSING FUSED RING SYSTEMS USEFUL AS PHOTOSELECTIVE COMPOUNDS FOR PHOTODYNAMIC THERAPY | PPOX, HMBS, DDT | FGF1 4618/4885SERPINC1 2070/4885HPSE 2930/4885 |
| US-20050226810-A1 | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis | PPOX, HMBS, MPI | FGF1 4782/4885SERPINC1 1120/4885HPSE 1985/4885 |
| US-20050137180-A1 | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy | PPOX, HMBS, PYCR1 | FGF1 3014/4885SERPINC1 1818/4885HPSE 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.